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chemia lasting 1.25 (n ~ 18), 2.5 (n = 20), 5 (n = 9), or 10 (n ~ 161 min, or
multiple episodes cumulating in 10 (2 x 5 min, n = 17) or 20 (4 x 5 min,
n = 13 or 2 x 10 min, n = 14) min of preconditioning ischemia time, all
followed by 5 min of reperfusion. Control rats (n ~ 22) were not precondi-
tioned. In separate groups, glycogen was determined before whereas infarct
size was determined after prolonged ischemia (45 min) and reperfusion (120
min). Myocardial glycogen levels and infarct size are shown as a function of
preconditioning ischemia time.
Protocol I, dogs received 45-min episodes of preconditioning ischemia (PC:
n = 7) or a comparable control period In ~ 9) before sustained CO; Proto-
col II was identical except polymyxin-B (PMX: 50 mg/kg) was administered
throughout the PC regimen (n = 6) or control period (n = 6). Blood flow to
the ischemic subendocardium was assessed during sustained CO by injec-
tion of rauiolabeled microspheres, and area of necrosis (AN) was delineated
by tetrazolium staining and expressed as a % of the area at risk of infarction
(ARI.
PC G + PC AD G + AD CP G+ CP CG G + CG
t P:5 0.05: one-way ANOVA and SNK multiple range test
Endo Flow (mllminlg) ANIAR (%)
Protocol I: Control 006 ± 0.02 19 ± 3
PC 0.09 ± 003 6 ± 2"
Protocol II: Control + PMX 001 ± 001 29 ± 5
PC + PMX 0.02 ± 001 10 ± 3\
" P < 0.01 vs Control: \ p < 0.01 vs Control + PMX
Michel Ovize, Jean F Aupetlt, Gilles Rioufol, Joseph Loufoua, Xavier Andre-Foust,
Yves Minaire. Hopital Cardiologique, Lyon, France; University Claude Bernard, Lyon,
France
Preconditioning (PC) prevents ventricular fibrillation (VF) in the rat heart. We
sought to determine whether this protective effect might: (11 apply to the pig
heart, (2) be related to modifications of electrophysiologic parameters. Forty-
eight anesthetized pigs underwent 40 min of LAD coronary artery occlusion
(CO) followed by 2 hours of reperfusion (R) Prior to this, PC hearts received
10 min of CO and 10 min of R. Area at risk and infarct size were measured by
injection of blue dye and triphenyltetrazolium staining, respectively. Duration
of subepicardial monophasic action potential (MAPD) and VF threshold were
measured at different time points of the experiment. As expected, infarct
size was significantly reduced in PC hearts, averaging 6 ± 4%' of the risk
region versus 28 ± 4% in controls (* p < 0.01). But, incidence of VF was
not reduced in the PC group: 69% vs 63% in the control group (p = NSI.
Furthermore, time to VF during the 40 minute CO was significantly shorter
in PC than in control hearts: 7 ± 2 min' vs 18 ± 2 min 1* p < 0.01). This was
associated with a significantly lower VF threshold and shortening of MAPD
in PC hearts at the onset of the sustained CO. At 3 min of ischemia, VF
threshold averaged 2.3 ± 1.7 mAIO in PC vs 4.1 ± 2.4 mA in controls (* p
< 0.01 vs control). MAPD averaged 197 ± 4 ms' in PC hearts versus 214 ±
4 ms in controls 1* p < 0.05). This suggests that preconditioning does not
prevent but accelerates ventricular fibrillation in pig hearts via a decrease
of the fibrillation threshold and a shortening of monophasic action potential
during the first minutes of the sustained ischemia.
Protocol I confirmed the expected reduction in infarct size in precondi-
tioned dogs vs. controls. Protocol II revealed that all PMX-treated dogs were
rendered profoundly ischemic during CO. Nonetheless, treatment with PMX
did not attenuate the reduction in infarct size achieved with preconditioning.
Thus, the PKC inhibitor polymyxin-B may exacerbate ischemia during CO:
this may contribute to the previously reported "increase" in infarct size in
preconditioned rabbits treated with this agent. Polymyxin-B did not, however,
block the cardioprotective effects of preconditioning in this canine model.
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1706-41 Preconditioning Shortens Action Potential Duration
and Lowers Ventricular Fibrillation Threshold in Pig
Hearts
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In addition, infarct size reduction correlated with glycogen depletion be-
fore prolonged ischemia (r = 0.98; 19 P < 0.001). Thus, increasing precondi-
tioning ischemia time results in progressive myocardial glycogen depletion
and infarct size reduction, reaching a maximal effect when the precondition-
ing ischemia time is :0:5 min. This maximal effect may be due to marked
depletion of myocardial glycogen stores before prolonged ischemia.
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The anti-infarct effect of ischemic preconditioning (PC) is partly due to adeno-
sine receptor-mediated opening of KATP channels. PC-mediated protection
may be potentiated by exogenous infusion of adenosine receptor agonists.
To test this hypothesis, pentobarbital anesthetized rabbits (n = 8/group) un-
derwent two cycles of 5 min regional ischemia and 5 min coronary reperfu-
sion (REP; i.e., PC) followed by 30 min ischemia and 3 h REP Rabbits received
either adenosine (AD; 0.01 mg/min); cyclopentyladenosine (CP; Al recep-
tor agonist; 0.001 mg/minl or CGS 21680 (CG; A2 receptor agonist; 001
mg/min), i. v. for 65 min starting 5 min before onset of REP KATP channels
were blocked with i.v. glibenclamide (G; 0.15 mglkg) 10 min before PC in the
absence or presence of AD, CP or CG. Infarct and risk (R; cm3) volume was
assessed with tetrazolium and microsphere autoradiography. Infarct size (IS)
was normalized to R. IS in absolute controls (i.e., no PC) was 51 ± 6% (mean
±SEMI
R 1.6± 1 1.8±0.2 1.6±0.2 1.4±0.1 1.9±0.1 1.4±0.3 2.0±0.2 1.2±0.1
IS 19±2 39±7t 27±7 37±6t 12± 1 44±9t 22±3 50±5t
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1706-21 Adenosine-mediated Myocardial Protection During
Preconditioning is Abolished by KATP Channel
Blockade in Rabbits
John G. Kingma Jr., Mette Hazenberg, Denis Simard, Jacques R. Rouleau. Laval
University, Quebec, Canada
Cardiodynamics were similar for the treatment groups; but heart rate-
blood pressure product was lower (p ::: 0.05) during CP infusion. Conclu-
sions: 1) PC markedly reduced IS; 2) PC-mediated protection was not po-
tentiated with exogenous AD, CP or CG; and 3) G abolished PC-mediated
protection withouVwith exogenous AD, CP or CG. These data indicate that
adenosine receptor activation and opening of KATP channels are involved in
Pc.
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The Protein Kinase C Inhibitor Polymyxin-B does not
Block Preconditioning-induced Cardioprotection in
the Canine Model
Karin Przyklenk, Robert A. Kloner. Heart Institute, Hospital of the Good Samaritan, Los
Angeles, CA; University ofSouthern California, Los Angeles, CA
In the rabbit model, administration of protein kinase C IPKCI inhibitors such
as polymyxin-B have been reported to attenuate the reduction in infarct size
achieved with ischemic preconditioning. Activation of PKC has therefore
been proposed to playa crucial role in the mechanism by which precon-
ditioning protects the heart from subsequent sustained coronary occlusion
(CO). However, the possible confounding effects of PKC inhibition on my-
ocardial blood flow were not assessed in these studies. We addressed this
issue in 28 dogs subjected to 1 h of sustained CO and 4-5 h of reperfusion. In
11 :30
1706-51 Calcitonin Gene-related Peptide Improves Recovery
from Reversible Myocardial Ischemia
Ravi N. Samy, Scott C. Silvestry, B. Zane Atkins, James W. Davis, R. Eric Lilly, David
C. Sabiston, Jr., Donald D. Glower. Duke University, Durham, NC
Calcitonin gene-related peptide (CGRP) has been found to have inotropic
properties and a short half-life. CGRP has been demonstrated to reduce is-
chemic injury in tissue flaps as well as to increase coronary artery flow, while
other available inotropes have been shown to impair recovery from myocar-
dial ischemia. Yet, a therapeutic role for CGRP in myocardial ischemia has
not been defined. Therefore, CGRP was compared to placebo in nine chron-
ically instrumented conscious dogs who underwent two 15 minute left an-
terior descending coronary artery occlusions separated by at least 24 hours
of reperfusion. Left ventricular transmural pressure and myocardial segment
length were measured at control and during reperfusion. Either CGRP (0.07
Ilg/kglmin) or saline placebo was randomly chosen and continuously infused
from 45 to 105 minutes of reperfusion. The alternative infusion was given
during the second study. Regional function was assessed using preload re-
cruitable work area (PRWA), a load-insensitive measure of regional myocar-
dial performance. PRWA was calculated as the area beneath the linear stroke
work vs. end-diastolic length relationship. Data are mean PRWA (% of con-
